New Investor Group Acquires 98% of Indaptus Therapeutics, Appoints New CEO, Completing Change of Control
INDP sits 17% above its 52-week low of $1.52.
Summary
A group of new investors, led by Yun Yao and including newly appointed CEO Junyi Dai, has acquired preferred stock convertible into 98% of Indaptus Therapeutics' common shares for $11.2 million, completing a change of control.
Key Events · Ownership and Investor Activity · INDP
-
Change of Control Completed
A group of new investors, including Yun Yao, Sino Lion Ventures Limited, Junyi Dai, Ting Yang, and Lina Deng, has acquired preferred stock convertible into 108,936,000 common shares, representing 97.98% of the company's outstanding stock.
-
New CEO Appointed
Junyi Dai, one of the reporting persons, was appointed Chief Executive Officer and a member of the Board of Directors, effective March 23, 2026.
-
Significant Investment
The investor group paid an aggregate purchase price of $11.2 million for the preferred stock, which converted into common shares on March 24, 2026.
-
Strategic Review Planned
The new controlling shareholders intend to review their investment and may engage in discussions regarding the company's business, operations, governance, strategy, capitalization, and future plans.
Analysis · INDP · Life Sciences
This Schedule 13D provides critical details following the previously announced change of control and highly dilutive financing. The filing identifies the new investor group that now beneficially owns nearly 98% of Indaptus Therapeutics' common stock, effectively taking over the company. The appointment of Junyi Dai as the new CEO from within this investor group signals a complete shift in leadership and strategic direction. This transaction, valued at $11.2 million, represents a substantial capital injection for the company, which recently reported a going concern warning and halted its lead clinical program. While this financing is crucial for the company's survival and provides a new path forward, it comes at the cost of extreme dilution for prior shareholders. Investors should monitor the new management's strategic initiatives and any further disclosures regarding the company's operational and financial plans under this new ownership.
At the time of this filing, INDP was trading at $1.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4M. The 52-week trading range was $1.52 to $19.91. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.